What was the market valuation of the US q fever market in 2024?

The market valuation of the US q fever market was $114.0 Million in 2024. Read More

What is the projected market valuation for the US q fever market by 2035?

The projected market valuation for the US q fever market is $1231.66 Million by 2035. Read More

What is the expected CAGR for the US q fever market during the forecast period 2025 - 2035?

The expected CAGR for the US q fever market during the forecast period 2025 - 2035 is 24.15%. Read More

What are the market segments for the US q fever market?

The market segments for the US q fever market include Type, Diagnosis, Treatment, and End User. Read More

What was the valuation for the Acute segment in the US q fever market in 2024?

The valuation for the Acute segment in the US q fever market was $45.0 Million in 2024. Read More

What is the projected valuation for the Chronic segment by 2035?

The projected valuation for the Chronic segment is $781.66 Million by 2035. Read More

How much was the market valuation for Serology Tests in 2024?

The market valuation for Serology Tests was $40.0 Million in 2024. Read More

What is the expected valuation for Antibiotics in the US q fever market by 2035?

The expected valuation for Antibiotics in the US q fever market is $800.0 Million by 2035. Read More

What was the market valuation for Patients as an end user in 2024?

The market valuation for Patients as an end user was $34.2 Million in 2024. Read More

US Q Fever Market

Q: Which companies are key players in the US q fever market?

Key players in the US q fever market include Inovio Pharmaceuticals, Merck & Co, Pfizer Inc, Boehringer Ingelheim, Sanofi, GSK, Novartis, and Baxter International. Read More

ID: MRFR/Pharma/17495-HCR

100 Pages

Vikita Thakur

Last Updated: April 06, 2026

US Q Fever Market Research Report By Type (acute, chronic), By Diagnosis (serology tests, others), By Treatment (antibiotics, surgery) and By End User (patients, hospitals, others) - Growth & Industry Forecast 2025 To 2035

US Q Fever Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)24.15%

2024 Market Size$ 114 Million

2025 Market Size$ 141.53 Million

2035 Market Size$ 1,231.66 Million

Key Players

Inovio Pharmaceuticals

Merck & Co

Pfizer Inc

Boehringer Ingelheim

Sanofi

GSK

Trends

Increased Awareness and Education
Advancements in Diagnostic Technologies
Regulatory Focus on Vaccines and Treatments

Opportunities

Enhanced Research Funding
Growing Veterinary Awareness
Rising Incidence of Q Fever Cases

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Type (USD Million)
  1. 4.1.1 Acute
  2. 4.1.2 Chronic
2. 4.2 Construction, BY Diagnosis (USD Million)
  1. 4.2.1 Serology Tests
  2. 4.2.2 Others
3. 4.3 Construction, BY Treatment (USD Million)
  1. 4.3.1 Antibiotics
  2. 4.3.2 Surgery
4. 4.4 Construction, BY End User (USD Million)
  1. 4.4.1 Patients
  2. 4.4.2 Hospitals
  3. 4.4.3 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Inovio Pharmaceuticals (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck & Co (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Pfizer Inc (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Boehringer Ingelheim (DE)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Sanofi (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 GSK (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novartis (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Baxter International (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS
4. 6.4 US MARKET ANALYSIS BY TREATMENT
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CONSTRUCTION
9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
12. 6.12 CONSTRUCTION, BY TYPE, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 CONSTRUCTION, BY DIAGNOSIS, 2024 (% SHARE)
15. 6.15 CONSTRUCTION, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
16. 6.16 CONSTRUCTION, BY TREATMENT, 2024 (% SHARE)
17. 6.17 CONSTRUCTION, BY TREATMENT, 2024 TO 2035 (USD Million)
18. 6.18 CONSTRUCTION, BY END USER, 2024 (% SHARE)
19. 6.19 CONSTRUCTION, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
  3. 7.2.3 BY TREATMENT, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Q Fever Market Segmentation

US Q Fever Market By Type (USD Million, 2025-2035)

Acute
Chronic

US Q Fever Market By Diagnosis (USD Million, 2025-2035)

Serology Tests
Others

US Q Fever Market By Treatment (USD Million, 2025-2035)

Antibiotics
Surgery

US Q Fever Market By End User (USD Million, 2025-2035)

Patients
Hospitals
Others

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”